Merck & Co., Inc. $MRK Shares Bought by Quilter Plc

Quilter Plc raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 0.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,191,309 shares of the company’s stock after buying an additional 8,471 shares during the period. Merck & Co., Inc. comprises about 2.1% of Quilter Plc’s holdings, making the stock its 15th largest holding. Quilter Plc’s holdings in Merck & Co., Inc. were worth $125,397,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. DLD Asset Management LP lifted its stake in Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after acquiring an additional 11,000,000 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Merck & Co., Inc. by 192.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock valued at $461,335,000 after acquiring an additional 3,618,532 shares in the last quarter. Invesco Ltd. increased its stake in Merck & Co., Inc. by 16.6% during the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the period. Ameriprise Financial Inc. increased its stake in Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares during the period. Finally, Corient Private Wealth LLC lifted its position in shares of Merck & Co., Inc. by 85.6% during the second quarter. Corient Private Wealth LLC now owns 4,937,948 shares of the company’s stock worth $390,896,000 after purchasing an additional 2,277,088 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $120.62 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company has a fifty day simple moving average of $117.72 and a 200-day simple moving average of $103.39. The stock has a market cap of $298.21 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same quarter in the prior year, the company posted $1.72 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MRK shares. Morgan Stanley raised their price objective on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a research note on Thursday, January 8th. TD Cowen increased their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. Bank of America raised their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Guggenheim upped their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $127.13.

Insiders Place Their Bets

In related news, CMO Chirfi Guindo sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares of the company’s stock, valued at $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.